Champions Oncology Q3 revenue down 6% to $12.0M; operating loss widens to $2.6M

CHAMPIONS ONCOLOGY, INC.

2024-Q3 EPS reported -$0.53 revenue$36,153,000

Q3 FY2024 revenue $12.0M, down from $12.8M YoY; gross margin fell to 34.7% from 39.7%.
Operating loss of $2.6M vs $2.5M a year ago; adjusted EBITDA loss of $1.7M.
Nine-month revenue $36.2M, down 11.4%; operating loss of $7.1M vs $2.7M loss YoY.
Cash and equivalents $4.5M at quarter end; no debt outstanding.
Company seeking capital for Corellia AI subsidiary; two lead targets progress toward licensing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported third quarter ended January 31, 2024 results: revenue $12.0 million.

Period: third quarter ended January 31, 2024
Revenue: $12.0 million
Result: reported results

Exact text from the filing

Champions Oncology Reports Quarterly Revenue of $12.0 Million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported first nine months of fiscal 2024 results: revenue $36.2 million.

Period: first nine months of fiscal 2024
Revenue: $36.2 million
Result: reported results

Exact text from the filing

For the first nine months of fiscal 2024, revenue decreased 11.4% to $36.2 million compared to $40.8 million for the first nine months of fiscal 2023.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

CHAMPIONS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-010569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.